title: Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.
abstract: Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European-Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin-paclitaxel regimen over cisplatin-cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer.
authors.affiliation: EORTC Gynecological Cancer Cooperative Group, Brussels, Belgium. martine.piccart@bordet.be
authors.forename: M J
authors.initials: MJ
authors.lastname: Piccart
authors.forename: K
authors.initials: K
authors.lastname: Bertelsen
authors.forename: G
authors.initials: G
authors.lastname: Stuart
authors.forename: J
authors.initials: J
authors.lastname: Cassidy
authors.forename: C
authors.initials: C
authors.lastname: Mangioni
authors.forename: E
authors.initials: E
authors.lastname: Simonsen
authors.forename: K
authors.initials: K
authors.lastname: James
authors.forename: S
authors.initials: S
authors.lastname: Kaye
authors.forename: I
authors.initials: I
authors.lastname: Vergote
authors.forename: R
authors.initials: R
authors.lastname: Blom
authors.forename: R
authors.initials: R
authors.lastname: Grimshaw
authors.forename: R
authors.initials: R
authors.lastname: Atkinson
authors.forename: K
authors.initials: K
authors.lastname: Swenerton
authors.forename: C
authors.initials: C
authors.lastname: Trope
authors.forename: M
authors.initials: M
authors.lastname: Nardi
authors.forename: J
authors.initials: J
authors.lastname: Kaern
authors.forename: S
authors.initials: S
authors.lastname: Tumolo
authors.forename: P
authors.initials: P
authors.lastname: Timmers
authors.forename: J-A
authors.initials: JA
authors.lastname: Roy
authors.forename: F
authors.initials: F
authors.lastname: Lhoas
authors.forename: B
authors.initials: B
authors.lastname: Lidvall
authors.forename: M
authors.initials: M
authors.lastname: Bacon
authors.forename: A
authors.initials: A
authors.lastname: Birt
authors.forename: J
authors.initials: J
authors.lastname: Andersen
authors.forename: B
authors.initials: B
authors.lastname: Zee
authors.forename: J
authors.initials: J
authors.lastname: Paul
authors.forename: S
authors.initials: S
authors.lastname: Pecorelli
authors.forename: B
authors.initials: B
authors.lastname: Baron
authors.forename: W
authors.initials: W
authors.lastname: McGuire
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002170:Canada; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008137:Longitudinal Studies; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis
chemical_list: D003520:Cyclophosphamide; D017239:Paclitaxel; D002945:Cisplatin